Halozyme Therapeutics HALO Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $1.4B+37.6% | $1.02B+22.4% | $829.25M+25.6% | $660.12M+48.9% | ||
| $228.77M+43.5% | $159.42M-17.1% | $192.36M+38.1% | $139.3M+71.1% | ||
| $1.17B+36.4% | $855.91M+34.4% | $636.89M+22.3% | $520.81M+43.9% | ||
| 83.6%-0.7pp | 84.3%+7.5pp | 76.8%-2.1pp | 78.9%-2.7pp | ||
| $81.49M+3.1% | $79.05M+3.5% | $76.36M+14.6% | $66.61M+86.7% | ||
| $207.09M+34.2% | $154.34M+3.5% | $149.18M+3.9% | $143.53M+185% | ||
| $927.61M+100.0% | $463.85M-5.7% | $491.68M+25.2% | $392.59M+135% | ||
| —— | $551.48M+63.4% | $337.57M+26.2% | $267.53M-3.0% | ||
| $18.13M+0.2% | $18.1M-3.6% | $18.76M+10.7% | $16.95M+125% | ||
| $21.47M-9.6% | $23.75M+45.6% | $16.32M+1,460% | $1.05M-5.1% | ||
| —— | $557.13M+59.9% | $348.33M+39.9% | $248.92M+0.2% | ||
| $149.99M+32.7% | $113.04M+69.4% | $66.74M+42.6% | $46.79M+130% | ||
| —— | $444.09M+57.7% | $281.59M+39.3% | $202.13M-49.8% | ||
| —— | $3.43+62.6% | $2.11+45.5% | $1.45-47.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Halozyme Therapeutics's revenue?
- Halozyme Therapeutics (HALO) generated $1.5B in revenue over the trailing twelve months, up 39.1% year over year.
- Is Halozyme Therapeutics profitable?
- Halozyme Therapeutics reported $608.5M in net income over the trailing twelve months, a 47.9% net margin.
- What are Halozyme Therapeutics's profit margins?
- Gross margin is 82.8% and operating margin is 59.3%, with a 47.9% net margin.
- What is Halozyme Therapeutics's earnings per share?
- Halozyme Therapeutics's diluted EPS over the trailing twelve months is $4.91.
- Where does Halozyme Therapeutics's income statement data come from?
- Every line is extracted from Halozyme Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
